Because α- and β-secretases need to compete for the process of APP cleavage, and the cleavage of APP by α-secretase prevents the Aβ formation, two strategies have become very promising in developing drugs targeting these two secretases to overturn the neuropathological changes linked with most AD symptoms: increasing the activity of α-secretase or decreasing the activity of β-secretase [122]. Here, APP is linked to Alzheimer disease.